Asthma And Chronic Obstructive Pulmonary Disease (COPD) Drugs Global Market Report 2025

The asthma and COPD drugs market size has grown strongly in recent years. It will grow from $32.52 billion in 2024 to $35.66 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. This growth during the historical period is primarily attributed to increasing levels of air pollution, a rise in smoking habits, heightened awareness of respiratory illnesses, growing usage of corticosteroids and bronchodilators, and an increase in healthcare spending.

The asthma and COPD drugs market size is expected to see strong growth in the next few years. It will grow to $50.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. This anticipated growth is driven by the rising preference for personalized treatment approaches, the growing use of biologics and next-generation therapies, a surge in environmental allergy cases, expansion in clinical trials and regulatory approvals, and the increasing prevalence of chronic non-communicable diseases. Notable trends projected during the forecast period include the emergence of smart inhaler technologies, development of dual-action bronchodilators, integration of drug data with electronic health records (EHRs), advancements in biopharmaceutical innovations, and the application of machine learning in the drug development process.

Major players in the asthma and COPD drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. (Roche), Merck & Co. Inc., Sanofi, AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc (GSK), Eli Lilly and Company, Amgen, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma, AptarGroup, Chiesi Farmaceutici S.p.A., Dr. Reddy’s Laboratories, Cipla Inc., Lupin Limited, Zydus Cadila, Glenmark Pharmaceuticals, Vectura Group, and Aurobindo Pharma.

North America was the largest region in the asthma and COPD drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in asthma and COPD drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the asthma and COPD drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The asthma and COPD drugs market consists of sales of bronchodilators, inhaled corticosteroids, combination inhalers, leukotriene modifiers, biologics, theophylline, and systemic corticosteroids. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.